NI-0801

Phase 2Small molecule

LLight Chain Bioscience - Novimmune SA

NI-0801 is one of 41 small molecule programs targeting Allergic Contact Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic Contact DermatitisActive, not recruiting

Primary Biliary CirrhosisActive, not recruiting

Allergic Contact DermatitisPhase 1

Active, not recruiting

Primary Biliary CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Primary Biliary Cirrhosis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Approved

1 2

Viread

Olumiant

Emtriva

Retrovir

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—7

Trexall

Alnylam Pharmaceuticals

Phase 3

3 8

Actigall

AbbVie

Phase 3

2 9

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 10

Iqirvo

Ipsen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Biliary Cirrhosis1 trial

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody

Terminated·LLight Chain Bioscience - Novimmune SA·Phase 2·NCT01430429

Allergic Contact Dermatitis1 trial

NI-0801 in Allergic Contact Dermatitis

Completed·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT01244607·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NI-0801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NI-0801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NI-0801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Light Chain Bioscience - Novimmune SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLight Chain Bioscience - Novimmune SA

NI-0801

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Biliary Cirrhosis1 trial

Allergic Contact Dermatitis1 trial

References

Drug Info

Quick Facts

Related News